Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.

Nguyen T, Parker R, Hawkins E, Holkova B, Yazbeck V, Kolluri A, Kmieciak M, Rahmani M, Grant S.

Oncotarget. 2019 Sep 3;10(51):5383-5384. doi: 10.18632/oncotarget.27175. eCollection 2019 Sep 3.

2.

The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo.

Zhang Y, Zhou L, Bandyopadhyay D, Sharma K, Allen AJ, Kmieciak M, Grant S.

Clin Cancer Res. 2019 Oct 15;25(20):6195-6205. doi: 10.1158/1078-0432.CCR-18-3788. Epub 2019 Jul 29.

PMID:
31358538
3.

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.

Gordon SW, McGuire WP 3rd, Shafer DA, Sterling RK, Lee HM, Matherly SC, Roberts JD, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmieciak M, Nguyen T, Deng X, Bandyopadhyay D, Dent P, Poklepovic AS.

Am J Clin Oncol. 2019 Aug;42(8):649-654. doi: 10.1097/COC.0000000000000567.

PMID:
31305287
4.

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.

Zhou L, Zhang Y, Leng Y, Dai Y, Kmieciak M, Kramer L, Sharma K, Wang Y, Craun W, Grant S.

J Hematol Oncol. 2019 Mar 7;12(1):25. doi: 10.1186/s13045-019-0713-x.

5.

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.

Nguyen T, Parker R, Zhang Y, Hawkins E, Kmieciak M, Craun W, Grant S.

BMC Cancer. 2018 Nov 16;18(1):1129. doi: 10.1186/s12885-018-5018-x.

6.

Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers.

Poklepovic A, Qu Y, Dickinson M, Kontos MC, Kmieciak M, Schultz E, Bandopadhyay D, Deng X, Kukreja RC.

Cardiooncology. 2018;4. pii: 7. doi: 10.1186/s40959-018-0033-2. Epub 2018 Aug 29.

7.

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.

Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B.

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):569-575.e1. doi: 10.1016/j.clml.2018.05.023. Epub 2018 Jun 6.

PMID:
30122201
8.

Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.

Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, Leverson JD, Sampath D, Ferreira-Gonzalez A, Grant S.

Cancer Res. 2018 Jun 1;78(11):3075-3086. doi: 10.1158/0008-5472.CAN-17-3024. Epub 2018 Mar 20.

9.

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.

Zhou L, Zhang Y, Sampath D, Leverson J, Dai Y, Kmieciak M, Nguyen M, Orlowski RZ, Grant S.

Br J Cancer. 2018 Feb 6;118(3):388-397. doi: 10.1038/bjc.2017.432. Epub 2017 Dec 14.

10.

Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.

Nguyen T, Parker R, Hawkins E, Holkova B, Yazbeck V, Kolluri A, Kmieciak M, Rahmani M, Grant S.

Oncotarget. 2017 May 9;8(19):31478-31493. doi: 10.18632/oncotarget.15649. Erratum in: Oncotarget. 2019 Sep 03;10(51):5383-5384.

11.

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.

Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, Shea TC, Grant S.

Leuk Lymphoma. 2017 Jun;58(6):1349-1357. doi: 10.1080/10428194.2016.1276287. Epub 2017 Jan 19.

12.

Phase I study of pemetrexed with sorafenib in advanced solid tumors.

Poklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE Jr, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent P.

Oncotarget. 2016 Jul 5;7(27):42625-42638. doi: 10.18632/oncotarget.9434.

13.

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.

Zhou L, Chen S, Zhang Y, Kmieciak M, Leng Y, Li L, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Rahmani M, Povirk L, Chalasani S, Berger AJ, Dai Y, Grant S.

Blood. 2016 May 5;127(18):2219-30. doi: 10.1182/blood-2015-06-653717. Epub 2016 Feb 5.

14.

Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.

Rahmani M, Aust MM, Hawkins E, Parker RE, Ross M, Kmieciak M, Reshko LB, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Grant S.

Haematologica. 2015 Dec;100(12):1553-63. doi: 10.3324/haematol.2015.130351. Epub 2015 Oct 9.

15.

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S.

Clin Cancer Res. 2016 Mar 1;22(5):1067-75. doi: 10.1158/1078-0432.CCR-15-1076. Epub 2015 Oct 7.

16.

Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.

Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW.

Leuk Lymphoma. 2016;57(3):635-43. doi: 10.3109/10428194.2015.1075019. Epub 2015 Oct 12.

17.

Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

Nguyen T, Hawkins E, Kolluri A, Kmieciak M, Park H, Lin H, Grant S.

Leuk Res. 2015 Jan;39(1):65-71. doi: 10.1016/j.leukres.2014.10.009. Epub 2014 Nov 11.

18.

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.

Zhou L, Zhang Y, Chen S, Kmieciak M, Leng Y, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Dai Y, Grant S.

Leukemia. 2015 Apr;29(4):807-18. doi: 10.1038/leu.2014.296. Epub 2014 Oct 6.

19.

Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.

Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S.

Clin Cancer Res. 2014 Nov 15;20(22):5652-62. doi: 10.1158/1078-0432.CCR-14-0805. Epub 2014 Sep 23.

20.

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.

Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S.

Blood. 2014 Oct 23;124(17):2687-97. doi: 10.1182/blood-2014-03-564534. Epub 2014 Sep 10.

21.

IFN-γ Rα is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse.

Kmieciak M, Payne KK, Wang XY, Manjili MH.

PLoS One. 2013 Dec 6;8(12):e82544. doi: 10.1371/journal.pone.0082544. eCollection 2013.

22.

Multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells.

El Shikh ME, Kmieciak M, Manjili MH, Szakal AK, Pitzalis C, Tew JG.

Hum Vaccin Immunother. 2013 Nov;9(11):2434-44. Epub 2013 Jul 8.

23.

The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.

Dai Y, Chen S, Kmieciak M, Zhou L, Lin H, Pei XY, Grant S.

Mol Cancer Ther. 2013 Jun;12(6):878-89. doi: 10.1158/1535-7163.MCT-12-0902. Epub 2013 Mar 27.

24.

A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.

Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S.

Clin Cancer Res. 2013 Apr 1;19(7):1873-83. doi: 10.1158/1078-0432.CCR-12-2926. Epub 2013 Mar 20.

25.

Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.

Toor AA, Payne KK, Chung HM, Sabo RT, Hazlett AF, Kmieciak M, Sanford K, Williams DC, Clark WB, Roberts CH, McCarty JM, Manjili MH.

Br J Haematol. 2012 Sep;158(6):700-11. doi: 10.1111/j.1365-2141.2012.09225.x. Epub 2012 Jul 23.

26.

Distinct oligoclonal T cells are associated with graft versus host disease after stem-cell transplantation.

Berrie JL, Kmieciak M, Sabo RT, Roberts CH, Idowu MO, Mallory K, Chung HM, McCarty JM, Borrelli CA, Detwiler MM, Kazim AL, Toor AA, Manjili MH.

Transplantation. 2012 May 15;93(9):949-57. doi: 10.1097/TP.0b013e3182497561.

PMID:
22377792
27.

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma.

Gowda M, Godder K, Kmieciak M, Worschech A, Ascierto ML, Wang E, Marincola FM, Manjili MH.

J Transl Med. 2011 Oct 6;9:170. doi: 10.1186/1479-5876-9-170.

28.

The role of Tyk2 in regulation of breast cancer growth.

Zhang Q, Sturgill JL, Kmieciak M, Szczepanek K, Derecka M, Koebel C, Graham LJ, Dai Y, Chen S, Grant S, Cichy J, Shimoda K, Gamero A, Manjili M, Bear H, Conrad D, Larner AC.

J Interferon Cytokine Res. 2011 Sep;31(9):671-7. doi: 10.1089/jir.2011.0023. Epub 2011 Aug 24.

29.

CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.

Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH.

Hum Pathol. 2012 Mar;43(3):364-73. doi: 10.1016/j.humpath.2011.05.005. Epub 2011 Aug 10.

PMID:
21835433
30.

Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.

Kmieciak M, Basu D, Payne KK, Toor A, Yacoub A, Wang XY, Smith L, Bear HD, Manjili MH.

J Immunol. 2011 Jul 15;187(2):708-17. doi: 10.4049/jimmunol.1100502. Epub 2011 Jun 13.

31.

A signature of immune function genes associated with recurrence-free survival in breast cancer patients.

Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY, Bear HD, Marincola FM, Manjili MH.

Breast Cancer Res Treat. 2012 Feb;131(3):871-80. doi: 10.1007/s10549-011-1470-x. Epub 2011 Apr 11.

32.

Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure.

Kmieciak M, Payne KK, Idowu MO, Grimes MM, Graham L, Ascierto ML, Wang E, Wang XY, Bear HD, Manjili MH.

J Transl Med. 2011 Mar 31;9:35. doi: 10.1186/1479-5876-9-35.

33.

Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation.

Kmieciak M, Toor A, Graham L, Bear HD, Manjili MH.

J Vis Exp. 2011 Jan 14;(47). pii: 2381. doi: 10.3791/2381.

34.

CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer.

Kmieciak M, Worschech A, Nikizad H, Gowda M, Habibi M, Depcrynski A, Wang E, Godder K, Holt SE, Marincola FM, Manjili MH.

Breast Cancer Res Treat. 2011 Apr;126(2):385-94. doi: 10.1007/s10549-010-0942-8. Epub 2010 May 18.

35.

GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.

Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH.

Breast Cancer Res Treat. 2010 Aug;123(1):39-49. doi: 10.1007/s10549-009-0622-8. Epub 2009 Nov 8.

36.

Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function.

Kmieciak M, Gowda M, Graham L, Godder K, Bear HD, Marincola FM, Manjili MH.

J Transl Med. 2009 Oct 22;7:89. doi: 10.1186/1479-5876-7-89.

37.

The Arabidopsis CBP20 targets the cap-binding complex to the nucleus, and is stabilized by CBP80.

Kierzkowski D, Kmieciak M, Piontek P, Wojtaszek P, Szweykowska-Kulinska Z, Jarmolowski A.

Plant J. 2009 Sep;59(5):814-25. doi: 10.1111/j.1365-313X.2009.03915.x. Epub 2009 May 12.

38.

Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.

Le HK, Graham L, Miller CH, Kmieciak M, Manjili MH, Bear HD.

Cancer Immunol Immunother. 2009 Oct;58(10):1565-76. doi: 10.1007/s00262-009-0666-y. Epub 2009 Feb 6.

39.

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells.

Morales JK, Kmieciak M, Graham L, Feldmesser M, Bear HD, Manjili MH.

Cancer Immunol Immunother. 2009 Jun;58(6):941-53. doi: 10.1007/s00262-008-0609-z. Epub 2008 Nov 1.

40.

Does HER-2/neu antigen loss in metastatic breast tumors occur under immune pressure?

Manjili MH, Kmieciak M.

Int J Cancer. 2008 Sep 15;123(6):1476-7; author reply 1478-9. doi: 10.1002/ijc.23663. No abstract available.

41.

Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis.

Habibi M, Kmieciak M, Graham L, Morales JK, Bear HD, Manjili MH.

Breast Cancer Res Treat. 2009 Apr;114(3):423-31. doi: 10.1007/s10549-008-0024-3. Epub 2008 Apr 20.

42.

Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.

Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E, Marincola FM, Manjili MH.

Cancer Res. 2008 Apr 1;68(7):2436-46. doi: 10.1158/0008-5472.CAN-07-6822.

43.

Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design.

Kmieciak M, Morales JK, Morales J, Bolesta E, Grimes M, Manjili MH.

Cancer Immunol Immunother. 2008 Sep;57(9):1391-8. doi: 10.1007/s00262-008-0475-8. Epub 2008 Feb 16.

44.

Comparison functioning and quality of life of patients with osteoarthritis and rheumatoid arthritis.

Baczyk G, Samborski P, Pieścikowska J, Kmieciak M, Walkowiak I.

Adv Med Sci. 2007;52 Suppl 1:55-9.

PMID:
18232100
45.

Surgical treatment of metastasic tumors to long bones in the material of the Unit.

Karwicki L, Kmieciak M, Kopka M.

Ortop Traumatol Rehabil. 2003 Jun 30;5(3):358-63.

PMID:
18034032
46.

Primary osseous rhabdomyosarcoma with focal matrix formation mimicking osteosarcoma.

Kordek R, Sowa P, Panasiuk M, Kmieciak M, Chudobinski C, Pluciennik E, Bednarek AK, Potemski P, Jesionek-Kupnicka D.

Pathol Res Pract. 2007;203(12):873-7. Epub 2007 Oct 1.

PMID:
17905523
47.

Tumor immunoediting and immunosculpting pathways to cancer progression.

Reiman JM, Kmieciak M, Manjili MH, Knutson KL.

Semin Cancer Biol. 2007 Aug;17(4):275-87. Epub 2007 Jun 26. Review.

48.
49.

[The phenomenon of spreading smoking cigarettes among the first year course students in the Medical Academy].

Bielawska A, Kmieciak M, Jedrasiak L, Walkowiak I, Baczyk G.

Przegl Lek. 2006;63(10):1031-7. Polish.

PMID:
17288209
50.

Comment on "Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma".

Manjili MH, Kmieciak M, Keeler J.

J Immunol. 2006 Apr 15;176(8):4511; author reply 4511-2. No abstract available.

Supplemental Content

Loading ...
Support Center